Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The study aims to investigate the olfactory TDI score (Threshold, Discrimination,
Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with
nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during
the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months
and 6 months).
The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders
- negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.